Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA NEAT1  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 29/January/2019, 5.23 am

Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing  probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as SAV1/WW45, PP2A, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 27/January/2019, `11.47 pm
January 27, 2019
Natural product-based therapy for attenuating pathogenesis-associated with Myocardial infarction: Quercetin, isolated from elderberries, onion and others, decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via upregulation of its target gene, 29/January/2018, 6.06 am
January 29, 2019
Show all

Introduction: What they say

A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney, New South Wales 2052, Australia shows that “A conserved NAD+ binding pocket that regulates protein-protein interactions during aging.” This research paper was published, in the 24 March 2017 issue of the journal “Science [One of the best research journals in Science with an I.F of 34+], by Prof. David A. Sinclair, Jun Li, and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA NEAT1  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene


What is known?

Prof. David A. Sinclair’s research team has recently shown that: (a) increased levels of NAD+ (found in non-aged tissues) inhibits the interaction the between DBC1 (deleted in breast cancer 1) and PARP1 [poly(adenosine diphosphate–ribose) polymerase]; and promotes DNA repair; (b) decreased levels of NAD+ (found in aged tissues) promotes the interaction between DBC1 and PARP1 and inhibits DNA repair; (c) aged cells/tissues that are low in NAD+ are radiation-sensitive, cancer-prone and prone to accelerated aging; and (d) aging-associated diseases can be reversed by increasing the concentration of NAD+ in aging tissues, suggesting that aging-associated diseases, in part, can be reversed by NAD+ supplementation in older animals.


From research findings to therapeutic opportunity:

This study suggests an RNA-based therapy for both aging-associated diseases and life-span extension. LncRNA NEAT1, by decreasing the expression of its target gene, it may increase the levels of NAMPT and NMN/NAD+. Thereby, it may: (1) increase plasma NMN levels and tissue NAD+ availability; (2) inhibit the interaction between DBC1 and PARP1; (3) augment PARP1’s DNA repair activity; (4) protect against radiation; (5) protect against cancer; and (6) prevent age-associated gene expression pattern and accelerated ageing. Thus, pharmacological formulations encompassing “lncRNA NEAT1 or its activators, either alone or in combination with other compounds,” may be used to suppress age-associated overall physiological decline and improve health/lifespan.[easy_payment currency=”USD”]

Figure1. LncRNA NEAT1 may act as an anti-aging and a longevity-promoting agent. LncRNA NEAT1, by increasing NAD+ levels, may suppress aging-associated overall physiological decline, aging-associated diseases and improve health/lifespan

Figure 2. LncRNA NEAT1 promotes health/life-span.


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does LncRNA NEAT1 increase the levels of NMN/NAD?

Amount: $300#

* Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Citation: Boominathan, L., Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA NEAT1  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 29/January/2019, 5.23 am, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite us, kindly drop us a line

Comments are closed.